Canaccord Genuity Raises 2012 Estimates on GenMark Diagnostics (GNMK); Sales Force Expansion & Improved Lab Utilization
Tweet
Share
E-mailGet Alerts GNMK Hot Sheet
Price: $24.04 --0%
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
2 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK) price target of $12.00.
Analyst, Jeffrey Frelick, said, "We reiterate our BUY on GNMK after management raised its revenue outlook for Q2 and full-year 2012 by 50% to reflect higher test utilization...We raise our 2012 revenue estimate to $15.1M (+201% Y/Y), up from $11.4M. We raise 2012E EPS by $0.04 to ($1.23) and our GM projection by 690bps to 34.8%. We are maintaining our 2013 estimates at this time.
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $4.45 yesterday.
Analyst, Jeffrey Frelick, said, "We reiterate our BUY on GNMK after management raised its revenue outlook for Q2 and full-year 2012 by 50% to reflect higher test utilization...We raise our 2012 revenue estimate to $15.1M (+201% Y/Y), up from $11.4M. We raise 2012E EPS by $0.04 to ($1.23) and our GM projection by 690bps to 34.8%. We are maintaining our 2013 estimates at this time.
For an analyst ratings summary and ratings history on GenMark Diagnostics click here. For more ratings news on GenMark Diagnostics click here.
Shares of GenMark Diagnostics closed at $4.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Raymond James Starts Southern California Bancorp (BCAL) at Outperform
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
